Lv1
68 积分 2023-02-20 加入
Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies
1年前
已完结
TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease
1年前
已完结
Pathophysiology of Inflammatory Bowel Diseases
1年前
已完结
Novel treatments in B cell non-Hodgkin’s lymphomas
1年前
已完结
Expert Perspective: An Approach to Refractory Lupus Nephritis
1年前
已完结
Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus–associated refractory cerebral vasculitis induces immune tolerance
1年前
已完结
Clinical trials in systemic lupus erythematosus: the dilemma—Why have phase III trials failed to confirm the promising results of phase II trials?
1年前
已完结
Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus
1年前
已完结
皖公网安备34019202002308
